GSK2239633

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 1

Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633

CompletedNCT01086462

GlaxoSmithKlineAsthma

Start: 2010-01-21End: 2010-02-22Updated: 2017-07-18

GSK2239633 FTIH Study

CompletedNCT01371812

GlaxoSmithKlineAsthma

Start: 2011-03-29End: 2011-07-01Updated: 2017-07-21

Related Papers

Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study.

2013-02-2838 citations